Oncolytics Biotech Inc. (ONCY)
Market Cap | 82.96M |
Revenue (ttm) | n/a |
Net Income (ttm) | -27.75M |
Shares Out | 75.42M |
EPS (ttm) | -0.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 111,855 |
Open | 1.090 |
Previous Close | 1.080 |
Day's Range | 1.060 - 1.100 |
52-Week Range | 0.880 - 3.390 |
Beta | 1.46 |
Analysts | Strong Buy |
Price Target | 5.50 (+404.59%) |
Earnings Date | May 7, 2024 |
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelare... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 404.59% from the latest price.
News
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
SAN DIEGO and CALGARY, AB , April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announ...
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic bre...
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
SAN DIEGO and CALGARY, AB , April 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Pres...
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response...
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer p...
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a cl...
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
SAN DIEGO and CALGARY, AB , Feb. 28, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chie...
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - February 15, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on c...
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion SAN DIEGO and CALGARY, Alb...
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
SAN DIEGO and CALGARY, AB , Jan. 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appoi...
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant...
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the expansion of existing TI...
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta , Nov. 9, 2023 /PRNewswire...
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
Updated plan follows PanCAN's strategic re-evaluation of the Precision PromiseSM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as planned New Phase 3 str...
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelareorep's ability to increase PD-L1 positive c...
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Cancer Action Network (PanCAN) provides fi...
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and CALGARY, ...
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action SAN DIEGO and CALGARY, AB , Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASD...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Oct. 20, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a c...
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO and CALGARY, AB , Oct. 16, 2023 /PRNewsw...
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON and SAN DIEGO and CALGARY, AB , Sept. 26, 2023 /PRNewswi...
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
SAN DIEGO and CALGARY, AB , Sept. 19, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its part...
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and CALGARY, AB , Sept. 6, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside...
Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights
Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression P...